LeMaitre Vascular reported preliminary Q2 2026 results with sales of $70.4 million, a 10% increase year-over-year, and diluted EPS of $0.74. The company announced a quarterly cash dividend of $0.25 per share, payable on September 3, 2026 to shareholders of record as of August 20, 2026. Management provided full-year 2026 guidance projecting sales between $274.3 million and $278.3 million (midpoint $276.3 million) and adjusted EPS between $2.84 and $2.94. LeMaitre Vascular develops, manufactures, and markets disposable and implantable vascular devices for the treatment of peripheral vascular disease.

LeMaitre Vascular, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, with 21,336,301 shares represented. Stockholders elected two Class II directors, approved executive compensation with 19,311,813 votes in favor, and ratified Grant Thornton LLP as the independent registered public accounting firm with 21,220,412 votes in favor.